Temperature-controlled solutions company Cryoport has completed the sale of its courier business, focused on focused on clinical trials, biopharma, and cell and gene therapies, to logistics provider DHL Group.
First announced in , the transaction was valued at around $200m.
Jerrell Shelton, CEO of Cryoport, said the divestment aligns with the company’s long-term strategic vision and allows the company to intensify its focus on advancing its life science service platform.
In addition to the sale, Cryoport and DHL have also formed a strategic partnership to work together on supply chain and logistics opportunities in the life sciences and healthcare sectors.
… to continue reading this article and more, please login, register for free, or consider subscribing to gasworld
You’ve reached your weekly limit to access free articles!
Want to keep reading?
Please register for free and create a profile to gain access to this full article and gasworld’s daily news.
For access to more content including our monthly digital magazines, subscriber-only features or columns and all our other gasworld archives, please consider subscribing.
Alternatively, you can continue reading more articles as a guest on Tuesday, 17th June at 4:31PM
